Teva and Sun Pharmaceuticals have been in discussions with the U.S. Department of Justice to settle a price-fixing probe into generic pharmaceutical pricing. The stakes are high given convictions could prevent firms from working with Medicare / Medicaid according to Bloomberg. U.S. seaborne imports associated with Teva climbed 29.9% year over year in October after a 13.3% rise in 3Q, potentially indicating expectations of business-as-usual. Teva has a diverse sourcing base while 83.9% of shipments linked to Sun Pharma were sourced from India. Sun Pharma’s shipments have also sur...